-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Friday, AbCellera's ABCL575 Matches Clinical Benchmark And Demonstrates Extended Half-Life In Preclinical AD Studies

Benzinga·05/12/2025 07:40:17
Listen to the news
  • ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD)
  • In preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark